165 related articles for article (PubMed ID: 38050021)
21. The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.
van Dessel LF; van Riet J; Smits M; Zhu Y; Hamberg P; van der Heijden MS; Bergman AM; van Oort IM; de Wit R; Voest EE; Steeghs N; Yamaguchi TN; Livingstone J; Boutros PC; Martens JWM; Sleijfer S; Cuppen E; Zwart W; van de Werken HJG; Mehra N; Lolkema MP
Nat Commun; 2019 Nov; 10(1):5251. PubMed ID: 31748536
[TBL] [Abstract][Full Text] [Related]
22. Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.
Herberts C; Murtha AJ; Fu S; Wang G; Schönlau E; Xue H; Lin D; Gleave A; Yip S; Angeles A; Hotte S; Tran B; North S; Taavitsainen S; Beja K; Vandekerkhove G; Ritch E; Warner E; Saad F; Iqbal N; Nykter M; Gleave ME; Wang Y; Annala M; Chi KN; Wyatt AW
Eur Urol; 2020 Dec; 78(6):834-844. PubMed ID: 32451180
[TBL] [Abstract][Full Text] [Related]
23. Molecular pathology of prostate cancer revealed by next-generation sequencing: opportunities for genome-based personalized therapy.
Huang J; Wang JK; Sun Y
Curr Opin Urol; 2013 May; 23(3):189-93. PubMed ID: 23385974
[TBL] [Abstract][Full Text] [Related]
24. Elucidation of the Genomic-Epigenomic Interaction Landscape of Aggressive Prostate Cancer.
Kumar Mamidi TK; Wu J; Hicks C
Biomed Res Int; 2021; 2021():6641429. PubMed ID: 33511206
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive genomic profiling and treatment patterns across ancestries in advanced prostate cancer: a large-scale retrospective analysis.
Sivakumar S; Lee JK; Moore JA; Hopkins J; Newberg JY; Madison R; Graf R; Schrock AB; Kobetz E; Vince R; Franco I; Seldon C; Frampton GM; Mills J; Venstrom J; Mahal BA
Lancet Digit Health; 2023 Jun; 5(6):e380-e389. PubMed ID: 37236698
[TBL] [Abstract][Full Text] [Related]
26. Leveraging Veterans Health Administration Clinical and Research Resources to Accelerate Discovery and Testing in Precision Oncology.
Graff JN; Huang GD
Fed Pract; 2020 Aug; 37(Suppl 4):S62-S67. PubMed ID: 32908354
[TBL] [Abstract][Full Text] [Related]
27. The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform.
Morris LGT; Chandramohan R; West L; Zehir A; Chakravarty D; Pfister DG; Wong RJ; Lee NY; Sherman EJ; Baxi SS; Ganly I; Singh B; Shah JP; Shaha AR; Boyle JO; Patel SG; Roman BR; Barker CA; McBride SM; Chan TA; Dogan S; Hyman DM; Berger MF; Solit DB; Riaz N; Ho AL
JAMA Oncol; 2017 Feb; 3(2):244-255. PubMed ID: 27442865
[TBL] [Abstract][Full Text] [Related]
28. Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer.
Zhu J; Tucker M; Marin D; Gupta RT; Healy P; Humeniuk M; Jarvis C; Zhang T; McNamara M; George DJ; Wu Y; Lisi S; Armstrong AJ
Urol Oncol; 2019 Nov; 37(11):813.e1-813.e9. PubMed ID: 31327751
[TBL] [Abstract][Full Text] [Related]
29. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer.
Fraser M; Berlin A; Bristow RG; van der Kwast T
Urol Oncol; 2015 Feb; 33(2):85-94. PubMed ID: 24768356
[TBL] [Abstract][Full Text] [Related]
30. Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity.
Løvf M; Zhao S; Axcrona U; Johannessen B; Bakken AC; Carm KT; Hoff AM; Myklebost O; Meza-Zepeda LA; Lie AK; Axcrona K; Lothe RA; Skotheim RI
Eur Urol; 2019 Mar; 75(3):498-505. PubMed ID: 30181068
[TBL] [Abstract][Full Text] [Related]
31. Liquid Biopsies in a Veteran Patient Population With Advanced Prostate and Lung Non-Small Cell Carcinomas: A New Paradigm and Unique Challenge in Personalized Medicine.
Dalal S; Petersen J; Jhala D
Fed Pract; 2021 Jan; 38(1):8-14. PubMed ID: 33574643
[TBL] [Abstract][Full Text] [Related]
32. Machine Learning Methods to Predict Lung Cancer Survival Using the Veterans Affairs Research Precision Oncology Data Commons.
Do NV; Ramos JC; Fillmore NR; Grossman RL; Fitzsimons M; Elbers DC; Meng F; Johnson BR; Ajjarapu S; DeDomenico CL; Pierce-Murray KE; Hall RB; Do AF; Gaynor K; Elkin PL; Brophy MT
Stud Health Technol Inform; 2019 Aug; 264():1453. PubMed ID: 31438177
[TBL] [Abstract][Full Text] [Related]
33. Precision medicine for advanced prostate cancer.
Mullane SA; Van Allen EM
Curr Opin Urol; 2016 May; 26(3):231-9. PubMed ID: 26909474
[TBL] [Abstract][Full Text] [Related]
34. Towards precision oncology in advanced prostate cancer.
Ku SY; Gleave ME; Beltran H
Nat Rev Urol; 2019 Nov; 16(11):645-654. PubMed ID: 31591549
[TBL] [Abstract][Full Text] [Related]
35. Improving risk stratification among veterans diagnosed with prostate cancer: impact of the 17-gene prostate score assay.
Lynch JA; Rothney MP; Salup RR; Ercole CE; Mathur SC; Duchene DA; Basler JW; Hernandez J; Liss MA; Porter MP; Wright JL; Risk MC; Garzotto M; Efimova O; Barrett L; Berse B; Kemeter MJ; Febbo PG; Dash A
Am J Manag Care; 2018 Jan; 24(1 Suppl):S4-S10. PubMed ID: 29337486
[TBL] [Abstract][Full Text] [Related]
36. Comparative Analysis of Genomic Alterations across Castration Sensitive and Castration Resistant Prostate Cancer via Circulating Tumor DNA Sequencing.
Fan L; Fei X; Zhu Y; Pan J; Sha J; Chi C; Gong Y; Du X; Zhou L; Dong B; Xue W
J Urol; 2021 Feb; 205(2):461-469. PubMed ID: 32897803
[TBL] [Abstract][Full Text] [Related]
37. High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer -Results from a prospective pilot study using a 37 gene panel.
Nientiedt C; Endris V; Jenzer M; Mansour J; Sedehi NTP; Pecqueux C; Volckmar AL; Leichsenring J; Neumann O; Kirchner M; Hoveida S; Lantwin P; Kaltenecker K; Dieffenbacher S; Gasch C; Hofer L; Franke D; Tosev G; Görtz M; Schütz V; Radtke JP; Nyarangi-Dix J; Hatiboglu G; Simpfendörfer T; Schönberg G; Isaac S; Teber D; Koerber SA; Christofi G; Czink E; Kreuter R; Apostolidis L; Kratochwil C; Giesel F; Haberkorn U; Debus J; Sültmann H; Zschäbitz S; Jäger D; Duensing A; Schirmacher P; Grüllich C; Hohenfellner M; Stenzinger A; Duensing S
Urol Oncol; 2020 Jul; 38(7):637.e17-637.e27. PubMed ID: 32280037
[TBL] [Abstract][Full Text] [Related]
38. Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations.
Antonarakis ES; Shaukat F; Isaacsson Velho P; Kaur H; Shenderov E; Pardoll DM; Lotan TL
Eur Urol; 2019 Mar; 75(3):378-382. PubMed ID: 30337059
[TBL] [Abstract][Full Text] [Related]
39. Homologous recombination repair gene mutations in Chinese localized and locally advanced prostate cancer patients.
Jiang X; Hu X; Gu Y; Li Y; Jin M; Zhao H; Gao R; Huang Z; Lu J
Pathol Res Pract; 2021 Aug; 224():153507. PubMed ID: 34102435
[TBL] [Abstract][Full Text] [Related]
40. Accelerating precision medicine in metastatic prostate cancer.
Mateo J; McKay R; Abida W; Aggarwal R; Alumkal J; Alva A; Feng F; Gao X; Graff J; Hussain M; Karzai F; Montgomery B; Oh W; Patel V; Rathkopf D; Rettig M; Schultz N; Smith M; Solit D; Sternberg C; Van Allen E; VanderWeele D; Vinson J; Soule HR; Chinnaiyan A; Small E; Simons JW; Dahut W; Miyahira AK; Beltran H
Nat Cancer; 2020 Nov; 1(11):1041-1053. PubMed ID: 34258585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
